Skip to main content
. 2013 Jul 8;5(8):1227–1246. doi: 10.1002/emmm.201202258

Figure 5.

Figure 5

STI-1 promoted bone marrow derived cell (BMDC) viability, proliferation and trafficking in vitro
  1. The effect of recombinant STI-1 (Re-STI1) was studied in vitro using CD34+ BMDC culture. Mobilized peripheral blood samples were collected from rat femoral veins (5 mL) mobilized with recombinant human granulocyte colony-stimulating factor (rHuG-CSF, Kirin), and CD34+ BMDCs were isolated by magnetic bead separation method. Re-STI-1 in vitro concentration-dependently (0.1–1 µg/mL) increased BMDC viability 12 h post-treatment, measured by trypan blue exclusion assay (A), and BMDC proliferation 24 h post-treatment, detected by bromodeoxyuridine (BrdU) labelling (B). n = 8 per group.
  2. Migration of CD34+ BMDCs treated STI-1 was assessed by transwell migration assays. Re-STI-1 in vitro concentration-dependently (0.1–1 µg/mL) increased CD34+ BMDC migration over a 4 h incubation period in a trans-well migration assay, and this was inhibited by the PrPC blocking antibody (6H4, 6 µg/mL). Bone marrow chemokine stromal cell-derived factor 1α (SDF-1α, 100 ng/mL) served as a positive control. n = 8 per group.